Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Dec 30, 2019
|
staff reporter

NEW YORK – Eli Lilly said on Monday that its Phase III, LIBRETTO-531 clinical trial is

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Drug Discovery & Development

  1. Merck KGaA Discontinues Phase III Lung Cancer Trial of Bintrafusp Alfa

  2. Kuur Therapeutics Reports Initial Activity of CAR NK-Cell Therapy in Neuroblastoma

  3. In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health

  4. Transgene Begins Personalized Cancer Vaccine Study in Head, Neck Cancer

  5. Sutro Biopharma Advancing STRO-002 in Phase I Trial With Eye on Biomarker Strategies

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.